SBI Life Insurance Company Ltd (SBILIFE) Q1 FY27 Earnings Call: Guides 14-15% IRP Growth, VNB Grows 29% YoY

CompoundingAI Research Published July 24, 2026 5 min read

SBI Life Insurance Company Ltd held its Q1 FY27 earnings call on July 24, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Performance and Key Metrics

  • Total NBP of Rs.89.1 Bn — up 23% YoY in Q1 FY 2026-2027; private market share at 20.5%.
  • VNB reached Rs.14.1 Bn — growing 29% YoY (30% per alternate measure); VNB margin at 26.2% (27.4% excluding Rs.2.3 Bn GST impact).
  • PAT of Rs.7.2 Bn — up 22% YoY for Q1 FY 2026-2027; embedded value at Rs.852.9 Bn (+15% from June 2025).
  • Individual rated NBP grew 14% — to Rs.39.7 Bn, retaining 22.2% private market share and 15.2% total market share.
  • AUM crossed Rs.5.2 Tn — up 10% YoY; solvency ratio at 1.96 vs. regulatory minimum of 1.50.
  • Death claim settlement ratio at 98.8% — mis-selling ratio at industry-low 0.02%.

Portfolio Shift and Channel Dynamics

  • ULIP contribution to individual APE fell — from 65% in Q1 FY 2025-2026 to 61%; guaranteed non-par savings grew 27% to Rs.9.7 Bn in Q1 FY 2026-2027.
  • Non-ULIP share on IRP basis rose to 38% — at Q1 FY 2026-2027 end; management targets maintaining this mix for the full year FY 2026-2027.
  • Bancassurance (SBI & RRBs) individual APE grew 10% — to Rs.24.5 Bn; agency channel grew 20% to Rs.13.1 Bn in Q1 FY 2026-2027, reflecting sustained investment in 100+ branches over three years and the Agency Next program.
  • Other channels surged 160% — contributing 28% of total APE; other bank business grew 19% (corrected from 31%) with mix tilted 80% non-ULIP / 20% ULIP.
  • New corporate agency tie-up with J&K Bank — signed during Q1 FY 2026-2027; business expected to commence in Q2 FY 2026-2027.
  • Deferred annuity plan in pipeline — a regular pay deferred annuity plan expected to launch in Q2 FY 2026-2027.

VNB Walk, GST Impact, and Expense Trends

  • VNB margin at 26.2% landed at lower end of 26-28% guidance — pressured by lumpy group business at ~25% of APE vs. typical 10-12%; management described Q1 as a "one-off" and expects margins to move to the upper end over the remainder of FY 2026-2027.
  • Product mix impact of -60 bps entirely from GTL business — group margins are lower than individual; assumption change of -40 bps reflects base effect of an operating assumption change made in Q4 FY 2025-2026 (not a new change in Q1).
  • GST drag at 1.1% in Q1 FY 2026-2027 — down from 1.5% in Q4 FY 2025-2026; residual impact of 20-30 bps expected for FY26 (as termed by management), with impact persisting for one more quarter then fading.
  • Other expenses rose — driven by higher stamp duty linked to rising sum assured (especially protection) and labour court-related costs from employee additions; expected to streamline over the remaining three quarters of FY 2026-2027.
  • Full-year FY 2026-2027 guidance reiterated — IRP growth of 14-15% and VNB margin of 26-28%, with management targeting the upper end as product mix normalises.

Pure Protection Growth and Rider Attachment Trends

  • Individual pure protection APE grew 41% YoY — in Q1 FY 2026-2027; overall CT protection (individual + group) grew ~200%, driven by GTI business.
  • Individual protection mix shifting toward non-ROP — ROP at 68% vs. 73% in Q1 FY 2025-2026; non-ROP at 32%; protection APE growth subdued at ~15% (analyst estimate) due to lower ticket size on pure protection.
  • ULIP rider attachment reached 45-50% of policies — in Q1 FY 2026-2027, up from 35% at launch ~1.5 years ago and 45% ~1 year ago; driven by extending riders from traditional to unit-linked products and offering to existing customers.
  • Rider premiums classified under individual protection — not ULIP AP; management declined to quantify rider AP on the call but committed to sharing separately.
  • Group credit protect flat YoY — in Q1 FY 2026-2027; management expects an uptick in coming quarters.

Quality Indicators and Embedded Value Trends

  • 13th-month persistency improved to 87.7% — +61 bps YoY; 49th-month at 69.1% (+68 bps) in Q1 FY 2026-2027.
  • 61st-month persistency declined — due to a "COVID cohort" entering that bucket; management expects recovery to normal levels by end of Q3 FY 2026-2027 as the cohort exits.
  • Embedded value at Rs.852.9 Bn — up 15% from June 2025; solvency ratio at 1.96, well above the regulatory requirement of 1.50.
  • Assets under management at Rs.5.2 Tn — up 10% YoY; death claim settlement ratio at 98.8%; mis-selling ratio at 0.02%.
  • Regulatory landscape viewed positively — management believes the company is well-positioned (lowest surrender and grievance ratios, lowest commissions) and "expects future regulations to benefit the industry, similar to the positive impact of past regulations."

Guidance, New Initiatives, and Outlook

  • Full-year FY 2026-2027 guidance reaffirmed — IRP growth of 14-15% and VNB margin of 26-28% (targeting upper end); Q1 margin described as the bottom for the year.
  • Non-par product repricing in June 2026 — IRR improved for customers in line with yield curve movement, driving good traction; management closely monitors yields and reprices accordingly.
  • New product launch and distribution expansion — regular pay deferred annuity plan expected in Q2 FY 2026-2027; J&K Bank corporate agency tie-up to begin in Q2 FY 2026-2027.
  • Group business normalisation expected — as IRP contribution in total business normalises over the remainder of FY 2026-2027, VNB margins expected to revert toward the upper end of guidance.
  • No explicit long-term targets provided — management expressed confidence in growth supported by economic fundamentals, regulatory environment, and digital adoption, without committing to specific multi-year numeric goals.
Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now